U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H21N3
Molecular Weight 291.3901
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERLAPINE

SMILES

CN1CCN(CC1)C2=NC3=C(CC4=C2C=CC=C4)C=CC=C3

InChI

InChIKey=PWRPUAKXMQAFCJ-UHFFFAOYSA-N
InChI=1S/C19H21N3/c1-21-10-12-22(13-11-21)19-17-8-4-2-6-15(17)14-16-7-3-5-9-18(16)20-19/h2-9H,10-14H2,1H3

HIDE SMILES / InChI

Molecular Formula C19H21N3
Molecular Weight 291.3901
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Perlapine ‎is a sedative and hypnotic drug.The drug brand named Hypnodin contains generic salt-Perlapine and is manufactured by Takeda Pharmaceutical. Perlapine is a potent H1R inverse agonist. It showed robust sedative effects clinically. Perlapine belongs to antipsychotic drugs which elicit little or no Parkinsonism, it binds more loosely than dopamine to D2 receptors.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
2.7 µM [IC50]
9.7 null [pIC50]
60.0 nM [Kd]
100.0 nM [Kd]
30.0 nM [Kd]
13.0 nM [Kd]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Hypnodin

Doses

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
10 - 20 mg of perlapine nightly to improve sleep
Route of Administration: Oral
In Vitro Use Guide
Perlapine inhibited spiropiperidone binding at dopamine receptor D2 of rat with IC50 2.7uM
Substance Class Chemical
Record UNII
4N8UJJ27IM
Record Status Validated (UNII)
Record Version